Medical Devices

**Intuitive Surgical** (Nasdaq:ISRG) unveiled results from a comprehensive analysis of surgical results spanning various robotic operations. The prestigious Annals of Surgery has published a thorough examination of surgical outcomes over a 30-day period across seven cancer-related surgeries. This analysis compared […]

Boston-based Myomo (NYSE:MYO) has announced the pricing of a $15 million underwritten common stock offering. The wearable exoskeleton company is releasing 3 million shares at $5 each. Buyers have a 30-day window to purchase up to an additional 450,000 shares

Smith+Nephew (NYSE:SNN) has confirmed that job roles will be phased out in Tennessee, in response to an inquiry from MassDevice today. “Our aim is to evolve into a more efficient and dynamic entity,” a representative conveyed via email. “While optimizing

Field Medical announced it has secured the FDA breakthrough device designation for its FieldForce pulsed field ablation (PFA) system. Additionally, this technology has been accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP), which promotes preliminary, consistent strategic interactions

Acutus Medical has opted for a strategic realignment, envisioning a significant workforce reduction of 70%. Dr. Shaden Marzouk, the chair of Acutus’ board, characterized this downsizing as “hard but necessary steps.” Despite these layoffs, the company is determined to meet

***Solventum (NYSE: SOLV), formerly the Health Care division of 3M, has initiated a series of workforce reductions.*** The Star Tribune of Minnesota first reported the development through a video message by CEO Bryan Hanson directed to the Twin Cities headquarters’

Today, Withings revealed it has acquired approximately $22.5 million in backing as part of a fresh initiative supported by the French government. Through the France 2030 program, Withings is set to embark on “Project Deep” ( DE vice as a

Minneapolis-based ShiraTronics has officially commenced its pivotal FDA investigational device exemption (IDE) trial, aiming to assess its neuromodulation therapy for chronic migraines. The RELIEV-CM2 study marks the beginning of in-depth evaluation regarding the long-term safety and performance of this treatment.

Edwards Lifesciences (NYSE:EW) shared its ambitious growth trajectory as it transitions into a dedicated structural heart enterprise by 2025. This pivot follows the $4.2 billion divestment of its Critical Care division to BD, inciting a 3% global workforce reduction and

Today, a Texas hospital revealed its team of electrophysiologists successfully completed the inaugural procedures in the United States using the Affera platform by Medtronic (NYSE:MDT). Staff at the Texas Cardiac Arrhythmia Institute (TCAI) located at St. David’s Medical Center utilized